1 Wada T, Yasunaga H, Inokuchi R, et al. Effects of

edaravone on early outcomes in acute ischemic stroke

patients treated with recombinant tissue plasminogen

activator[J]. J Neurol Sci, 2014, 345:106-111.

2 Lasek-Bal A, Puz P, Kazibutowska Z. Efficacy and

safety assessment of alteplase in the treatment of

stroke-gender differences[J]. Neurol Res, 2014,

36:851-856.

3 Cuzick J, Thorat MA, Bosetti C, et al. Estimates of

benefits and harms of prophylactic use of aspirin in the

general population[J]. Ann Oncol, 2015, 26:47-57.

4 Hennekens CH, Dalen JE. Aspirin in the treatment

and prevention of cardiovascular disease:past and

current perspectives and future directions[J]. AM J

Med, 2013, 126:373-378.

5 Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of

aspirin on mortality in the primary prevention of

cardiovascular disease[J]. AM J Med, 2011, 124:621-629.

6 Dai Y, Ge J. Clinical use of aspirin in treatment and

prevention of cardiovascular disease[J]. Thrombosis,

2012:2012245037.

7 Connolly BJ, Pearce LA, Kurth T, et al. Aspirin

therapy and risk of subdural hematoma:meta-analysis

of randomized clinical trials[J]. J Stroke Cerebrovasc

Dis, 2013, 22:444-448.

8 Rist PM, Buring JE, Kase CS, et al. Effect of low-dose

aspirin on functional outcome from cerebral vascular

events in women[J]. Stroke, 2013, 44:432-436.

9 Xie M, Shan Z, Zhang Y, et al. Aspirin for primary

prevention of cardiovascular events:meta-analysis of

randomized controlled trials and subgroup analysis by

sex and diabetes status[J]. PLoS one, 2014, 9:e90286.

10 Soejima H, Ogawa H, Morimoto T, et al. Aspirin

possibly reduces cerebrovascular events in type

2 diabetic patients with higher C-reactive protein

level:subanalysis from the JPAD trial[J]. J Cardiol,

2013, 62:165-170.

11 Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin isbeneficial in hypertensive patients with chronic kidney

disease. a post-hoc subgroup analysis of a randomized

controlled trial[J]. J Am Coll Cardiol, 2010, 56:956-

965.

12 Ikeda Y, Shimada K, Teramoto T, et al. Low-dose

aspirin for primary prevention of cardiovascular

events in Japanese patients 60 years or older with

atherosclerotic risk factors:a randomized clinical

trial[J]. JAMA, 2014, 312:2510-2520.

13 Meschia JF, Bushnell C, Boden-Albala B, et al.

Guidelines for the primary prevention of stroke:a

statement for healthcare professionals from the

Amer ican Heart Association/Amer ican Stroke

Association[J]. Stroke, 2014, 45:3754-3832.

14 国家卫生计生委脑卒中防治工程委员会脑卒中防治

系列规范指导编审委员会. 中国脑卒中一级预防指导

规范[R]. 中国脑卒中大会2015, 北京, 2015-05-07.

15 Kim AJ, Lim HJ, Ro H, et al. Low-dose aspirin for

prevention of cardiovascular disease in patients with

chronic kidney disease[J]. PLoS one, 2014, 9:e104179.

16 Pinto A, Di Raimondo D, Tuttolomondo A, et al.

Antiplatelets in stroke prevention[J]. Curr Vasc

Pharmacol, 2013, 11:803-811.

17 Loke YK, White JR, Bettencourt-Silva JH, et al. Use

of antiplatelet drugs in stroke prevention:time for a

rethink?[J]. Postgrad Med J, 2013, 89:309-310.

18 Geeganage CM, Diener HC, Algra A, et al. Dual

or mono antiplatelet therapy for patients with acute

ischemic stroke or transient ischemic attack:systematic

review and meta-analysis of randomized controlled

trials[J]. Stroke, 2012, 43:1058-1066.

19 Apostolakis S, Marín F, Lip GY. Antiplatelet therapy

in stroke prevention[J]. Adv Cardiol, 2012, 47:141-154.

20 Bartolucci AA, Tendera M, Howard G. Meta-analysis

of multiple primary prevention trials of cardiovascular

events using aspirin[J]. Am J Cardiol, 2011, 107:1796-

1801.

21 Adelman EE, Lisabeth L, Brown DL. Gender

differences in the primary prevention of stroke with

aspirin[J]. Women Health, 2011, 7:341-352.

22 Gorelick PB, Weisman SM. Risk of hemorrhagic

stroke with aspirin use:an update[J]. Stroke, 2005,

36:1801-1807.